Surgery in high-volume hospitals not commission on cancer accreditation leads to increased cancer-specific survival for early-stage lung cancer.
Surgery in high-volume hospitals not commission on cancer accreditation leads to increased cancer-specific survival for early-stage lung cancer.
复制标题
DOI：
10.1016/j.amjsurg.2015.05.002
复制
发表时间：
2015-10
影响因子：
3
通讯作者：
Cress R
中科院分区：
文献类型：
--
作者：
David EA;Cooke DT;Chen Y;Perry A;Canter RJ;Cress R
肿瘤学结果的质量在非小细胞肺癌(NSCLC)患者的护理中至关重要。我们试图评估在加州治疗的NSCLC患者中叶切除的医院容量与癌症特异性生存率的关系，以及癌症委员会(CoC)认证的影响。从2004年到2011年，加州癌症登记处被查询了I期非小细胞肺癌的病例，确定了8,345名患者。统计分析被用来确定癌症特异性生存的预后因素。7587名患者接受了手术治疗。COC认证对癌症特异性存活率没有显著影响，但与低和中等量中心相比，高容量中心的治疗与更长的生存期相关(HR1.77，1.474-2.141和HR1.23，1.058-1.438)。这些数据表明，大容量医院的手术治疗与早期非小细胞肺癌的癌症特异性生存时间更长有关，但CoC认证并不相关。
Quality of oncologic outcomes is of paramount importance in the care of patients with non-small cell lung cancer (NSCLC). We sought to evaluate the relationship of hospital volume for lobectomy on cancer-specific survival in NSCLC patients treated in California, as well as the influence of Committee on Cancer (CoC) accreditation. The California Cancer Registry was queried from 2004–2011 for cases of Stage I NSCLC and 8,345 patients were identified. Statistical analysis was used to determine prognostic factors for cancer-specific survival. 7,587 patients were treated surgically. CoC accreditation was not significant for cancer-specific survival, but treatment in high volume centers was associated with longer survival when compared to low and medium volume centers (HR 1.77, 1.474–2.141 and HR 1.23, 1.058–1.438). These data suggest that surgical treatment in high volume hospitals is associated with longer cancer-specific survival for early-stage NSCLC, but that CoC accreditation is not.